Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer Journal Article
| Authors: | Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E. |
| Article Title: | Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer |
| Abstract: | Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare toxicities of PARPi. We describe three patients with germline BRCA-associated (gBRCA+) HGOC and alterations in AML driver genes. Although none evidenced overt hematologic malignancy, PARPi maintenance was cautiously considered given the potential risk of MDS/AML. A better understanding of the role of clonal hematopoiesis in the subsequent development of PARPi-associated MDS/AML will improve management of this patient population. |
| Keywords: | ovarian cancer; syndrome; brca mutation; acute myeloid leukemia; myelodysplastic; parp inhibitors |
| Journal Title: | Gynecologic Oncology Reports |
| Volume: | 38 |
| ISSN: | 2352-5789 |
| Publisher: | Elsevier B.V. |
| Date Published: | 2021-11-01 |
| Start Page: | 100873 |
| Language: | English |
| ACCESSION: | WOS:000710109400002 |
| DOI: | 10.1016/j.gore.2021.100873 |
| PROVIDER: | wos |
| PMCID: | PMC8651772 |
| PUBMED: | 34926756 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work